LSTA (Lisata Therapeutics) EPS (Basic): $-1.86 (TTM As of Mar. 2026)

What is Lisata Therapeutics EPS (Basic)?

Lisata Therapeutics LSTA -1.15% 19 EPS (Basic) is $-1.86 as of Mar. 2026. GuruFocus rates LSTA with a GF Score™ of 19/100. The stock has 4 warning signs investors should review.

Lisata Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.50. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.86.

Lisata Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.50. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.86.

Lisata Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was $-0.51. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -1.93.

During the past 3 years, the average EPS without NRI Growth Rate was 42.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 27.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 31.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Lisata Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 52.70% per year. The lowest was -22.20% per year. And the median was 27.10% per year.

Lisata Therapeutics (NAS:LSTA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Lisata Therapeutics EPS (Basic) Related Terms

Lisata Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Lisata Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lisata Therapeutics EPS (Basic) Chart

Lisata Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

-7.45

-10.47

-2.58

-2.40

-1.91

Lisata Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															-0.55	-0.54	-0.49	-0.33	-0.50

19GF Score

Lisata Therapeutics Inc LSTA

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Lisata Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Lisata Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-16.586	-	0)	/	8.687
	=	-1.91

Lisata Therapeutics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-4.489	-	0)	/	9.006
	=	-0.50

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.86

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of $-1.86 mean?

Lisata Therapeutics (LSTA) has a EPS (Basic) of $-1.86 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Lisata Therapeutics and its competitors.

Is Lisata Therapeutics' EPS (Basic) too high?

Lisata Therapeutics' current EPS (Basic) is $-1.86. Overall, Lisata Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.

How does Lisata Therapeutics' EPS (Basic) compare to NRSN and SNTI?

Lisata Therapeutics' EPS (Basic) of $-1.86 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Lisata Therapeutics and its competitors. Lisata Therapeutics's current EPS (Basic) is $-1.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Lisata Therapeutics stock overvalued right now?

Lisata Therapeutics (LSTA) has a current EPS (Basic) of $-1.86. The current EPS (Basic) is $-1.86. Lisata Therapeutics' overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Lisata Therapeutics (LSTA), the current EPS (Basic) is $-1.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lisata Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies NRSN SNTI DYAI CELU IGC CRVO NEUP APLM SNSE KYNB VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 0HS8:UK 8NE:Germany

Address 110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920

Website https://www.lisata.com

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.

19GF Score

Get the complete analysis for LSTA

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.45

Price

View LSTA Analysis

See EPS (Basic) data for all stocks →